To be fair, as much as the company is a horrible investment IMO, the CEO is living the dream. Anyone buying it deserves to part with their money.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling